Understanding how APOBEC proteins cause mutations in cancer cells
Molecular Mechanisms of APOBEC-Induced Mutagenesis in Cancer
This study is looking at how certain proteins in tumors can cause changes in their DNA, which might make them harder to treat, and it's aimed at helping cancer patients by finding better ways to tackle their disease.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-10993971 on NIH RePORTER |
What this research studies
This research investigates the role of APOBEC proteins in creating genetic diversity within tumors, which can lead to treatment resistance and cancer progression. By analyzing tumor samples and utilizing advanced sequencing technologies, the study aims to uncover the mechanisms behind DNA damage and repair failures that contribute to mutations. The goal is to identify how these mutations affect tumor behavior and response to therapies, ultimately leading to improved treatment strategies for patients with cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with various types of cancer who exhibit tumor heterogeneity and resistance to current treatments.
Not a fit: Patients with early-stage cancers that do not exhibit significant genomic instability may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that better target and manage cancer by addressing the underlying genetic mutations.
How similar studies have performed: Previous research has shown that understanding mutational signatures in cancer can lead to significant advancements in treatment strategies, indicating that this approach has potential for success.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Buisson, Remi — University of California-Irvine
- Study coordinator: Buisson, Remi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.